Clinical trial
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
NCT03792490 is registered in ClinicalTrials.gov with University Medical Center Goettingen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
- Lead sponsor
- University Medical Center Goettingen
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 20, 2019
- Completion date
- November 1, 2023
- Enrollment
- 120 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.